WHO Pipeline Review: “The world is running out of antibiotics”

Dear All: 

Released just a few hours ago in parallel with the UN General Assembly meetings, WHO has produced a detailed review of the global pipeline. As they note on their overview webpage, “The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including drug-resistant tuberculosis which kills around 250 000 people each year.”

The core report is here (and in the spirit of full disclosure, know that I contributed to the report). The only comparable analysis is the ongoing Pew Trust Antibiotic Pipeline Analysis, a series that has the advantage of providing pipeline snapshots every 3-6 months going back as far Feb 2014. The two analyses are (no surprise) very similar.

WHO has also released a new document describing their priority pathogen list. The list is unchanged from the initial release in February but the new document contains a lot of supplemental details.

From my perspective, the key message of the new WHO pipeline report is found in Section 5.3 (emphasis added by me): “Given the average success rates and development times in the past (18), the current pipeline of antibiotics and biologicals could lead to around 10 new approvals over the next 5 years. However, these new treatments will add little to the already existing arsenal and will not be sufficient to tackle the impending AMR threat. More investment is needed in basic science, drug discovery and clinical development, especially for the critical priority Gram-negative carbapenem-resistant pathogens P. aeruginosa, A. baumannii and Enterobacteriaceae.

Although those of us who are active in the field feel like we hear this message every day, many others (including key policy makers) do not fully appreciate the depth of the crisis. Kudos to WHO for releasing such a clear report in a timely fashion for the UNGA audience and to Pew for their longitudinal work to monitor the pipeline.

And for all of you engaged in antibiotic R&D, the message is clear … please get busy and find a few new (and preferably novel mechanism) drugs!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

In Praise of Non-Inferiority

Dear All (wonkish but intended for everybody to read and absorb): There’s been a lot of recent discussion about “lessons learned from COVID-19.” Indeed, there are many valuable points: global cooperation, preparedness, supply chains, and so forth. As an example, I note the 17 Sep 2020 communique from the G20 Health Ministers (link): it was heavily

FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference

Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference (go here or see below my signature for more), I had the opportunity on 27 August to chat with Sumati Nambiar (FDA) and Marco Cavaleri (EMA) about ongoing regulatory activities. The

Treating resistant Gram-negatives: IDSA provides pragmatic expert advice

Dear All, IDSA (Infectious Diseases Society of America) have today released an eagerly awaited new guidance document on treating infections due to resistant Gram-negative bacteria (link). The thing that makes this document unusual is that it is an expert guidance rather than a formal guideline. Although there is value in formal guidelines that carefully review

New antibiotics are not being registered or sold in Europe in a timely manner

Dear All (and with thanks to Kevin for leading the charge on this newsletter), While listening to last week’s BEAM-sponsored AMR Conference (really a wonderful conference, thank you Team BEAM, go here to listen to the sessions), we tumbled onto a really, really disturbing trend: New antibiotics are not being registered or sold in Europe in

Scroll to Top